Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Panaxia Labs Israel Ltd specializes in the development and manufacturing of pharmaceutical-grade cannabis products, primarily targeting the Israeli market. The company differentiates itself through proprietary extraction technologies and a robust distribution network, which positions it well in the rapidly growing medical cannabis sector.
Panaxia generates revenue by selling cannabis-based products to pharmacies and healthcare providers in Israel. The company's competitive advantages include its proprietary extraction methods that enhance product quality and consistency, as well as established relationships with key distributors in the medical cannabis space.
Changes in Israeli cannabis regulations that could expand market access
Product approval timelines for new cannabis formulations
Partnerships with healthcare providers or distributors
Market share shifts among competitors in the Israeli cannabis sector
Regulatory changes that could restrict cannabis sales or impose new compliance costs
Technological advancements by competitors that could outpace Panaxia's product offerings
Emergence of new entrants in the Israeli cannabis market with innovative products
Price competition from established players in the cannabis sector
Negative operating cash flow could limit the company's ability to invest in growth initiatives
High price-to-book ratio (9.9x) suggests potential overvaluation if growth does not materialize
moderate - The demand for medical cannabis can be sensitive to economic conditions, as consumer spending on healthcare products may fluctuate with economic cycles.
Interest rates impact financing costs for operational expansion and R&D investments, which are critical for growth in the cannabis sector. Higher rates could dampen expansion plans.
minimal - The company has a manageable debt-to-equity ratio of 0.66, indicating limited reliance on external credit.
growth - Investors looking for exposure to the expanding medical cannabis market may find Panaxia appealing.
high - The stock has shown significant price fluctuations, as evidenced by a 56.6% return over the past year.
